IDEXX LABORATORIES, INC.

(IDXX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
372.23 USD   +2.03%
05/19Goldman Sachs Adjusts IDEXX Laboratories' Price Target to $530 From $615, Maintains Neutral Rating
MT
05/18IDEXX Laboratories to Present at Stifel Conference and Announces 2022 Investor Day
PR
05/13IDEXX LABORATORIES INC /DE : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IDEXX Enables Improved Cancer Diagnosis and Personalized Care through Expanded Oncology Offering

01/13/2022 | 07:01am EDT

WESTBROOK, Maine, Jan. 13, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced today the expansion of its reference laboratory menu of tests and services that will enable veterinarians to better meet the challenges of diagnosing and treating cancer. Building on its expertise in cancer pathology, IDEXX continues to expand what's possible to enhance the lives of pets by providing veterinarians with comprehensive cancer diagnostics and support services.

"IDEXX understands the challenges that veterinarians are experiencing when it comes to diagnosing, staging, and treating cancer," said Jay Mazelsky, IDEXX President and Chief Executive Officer. "As veterinarians strive to advance the standard of care for their patients, we continue to support them through innovations like accessible genomic cancer diagnostic tests and services."

The extended menu, which will be available later this month to customers of IDEXX Reference Laboratories in the United States and Canada, includes:

  • A liquid biopsy test that utilizes next-generation DNA sequencing technology to aid in diagnosing the most common canine cancers: lymphoma, hemangiosarcoma, and osteosarcoma.
  • A diagnostic panel for biopsy tissues that is used to identify genetic mutations in canines, assisting in therapy selection and personalized treatment options.
  • Newly designed diagnostic profiles to support cancer therapy management and monitoring.

IDEXX's expanded oncology offering addresses the needs of a growing pet population and the increasing demand on veterinarians to diagnose and treat cancer. In the U.S. alone, roughly 6 million new cancer diagnoses are made in dogs, and a similar number are made in cats each year.1 Additionally, IDEXX's team of global pathologists review over 1 million suspected cancer case submissions annually.

Each cancer case is complex and can be overwhelming, especially considering the stress on both the patient and the pet owner. IDEXX creates clarity for veterinarians through the extended menu of cancer diagnostics and pathology services and by connecting them with medical experts that can provide guidance on managing cancer cases. IDEXX's expanded offering facilitates more efficient case management and patient care for general practitioners and oncology specialists.

For more information about IDEXX and its reference laboratory offerings, visit idexx.com/discovermore.

About IDEXX 
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, offering diagnostic and software products and services that deliver solutions and insights to practicing veterinarians around the world. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, tests for the quality and safety of water and milk, and point-of-care and laboratory diagnostics for human medicine. Headquartered in Maine, IDEXX employs approximately 9,800 people and offers products to customers in over 175 countries.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectation or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov and via IDEXX's website at idexx.com).

References

1 Animal Cancer Foundation 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-enables-improved-cancer-diagnosis-and-personalized-care-through-expanded-oncology-offering-301459598.html

SOURCE Idexx Laboratories, Inc.


© PRNewswire 2022
All news about IDEXX LABORATORIES, INC.
05/19Goldman Sachs Adjusts IDEXX Laboratories' Price Target to $530 From $615, Maintains Neu..
MT
05/18IDEXX Laboratories to Present at Stifel Conference and Announces 2022 Investor Day
PR
05/13IDEXX LABORATORIES INC /DE : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
05/05JPMorgan Adjusts Price Target for IDEXX Laboratories to $625 From $725, Maintains Overw..
MT
05/05Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $603 from $732, Keeps Overwe..
MT
05/05BofA Securities Downgrades IDEXX Laboratories to Neutral From Buy, Adjusts Price Target..
MT
05/04IDEXX LABORATORIES INC /DE Management's Discussion and Analysis of Financial Condition..
AQ
05/04SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Wednesday
MT
05/04TRANSCRIPT : IDEXX Laboratories, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04IDEXX Laboratories Q1 Earnings Slide, Revenue Rises; Company Lowers 2022 Outlook
MT
More news
Analyst Recommendations on IDEXX LABORATORIES, INC.
More recommendations